On July 23, Quest Diagnostics rose 8.71% in regular trading, trading at $232.0/share with turnover of $46.30 million. The surge was driven by the company's Q2 earnings report that significantly exceeded market expectations, accompanied by an upward revision of full-year guidance.

Quest Diagnostics reported Q2 adjusted EPS of $3.12, beating the analyst consensus estimate of $2.83 by 10.25% and representing a 19.08% year-over-year increase from $2.62. Revenue reached $3.04 billion, surpassing the $2.97 billion estimate and up from $2.76 billion a year earlier. The company raised its full-year 2026 adjusted EPS guidance to $11.05-$11.25, well above the FactSet consensus of $10.75, and full-year revenue guidance to $11.95-$12.05 billion versus the $11.85 billion estimate.

This marks the second consecutive quarter of beats and guidance raises, following a Q1 upward revision to $10.63-$10.83 EPS. Management noted stable health plan pricing with slight upward trends, while ACA exchange business remained balanced as fewer physician requests were offset by increased tests per request. The consistent outperformance reflects robust diagnostic service demand and operational efficiency gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)